Peru Medical Device Registration Pathway Selection 2026: Class I-IV Strategy Guide
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
Regulatory information verified as of October 29, 2026
1. Key takeaways
The market access route for a medical device in Peru is decided directly by its classification level: Class I proceeds through the inscription (registration) procedure, while Class II through IV proceed through the full sanitary registration procedure, and the two tracks diverge sharply in documentation depth, review clocks and official fees. Classification is governed by D.S. N° 003-2020-SA, published on 2020-02-06, whose Anexo 1 contains 18 classification rules; the determination is made by applying rules, not by consulting a product catalogue. Treating a low level as if it meant no regulatory obligation at all is the most costly misjudgment a manufacturer can make when selecting a pathway. The level dictates how deep the dossier must go, how long the review clock runs and which fee line applies, but every class requires a submission, a review and a registered holder who carries post-market duties. Getting the level right at project initiation, before any dossier is drafted, is therefore the single decision on which the entire downstream program depends.
2. Legal basis
| Regulation | Number | Publication date | Provisions / key points |
|---|---|---|---|
| Reglamento que establece las Reglas de Clasificación y los Principios Esenciales… | D.S. N° 003-2020-SA | 2020-02-06 | Anexo 1 contains 18 classification rules (non-invasive / invasive / active / additional rules); establishes the essential principles (Principios Esenciales de Seguridad y Desempeño) |
| Reglamento para el Registro, Control y Vigilancia Sanitaria… | D.S. N° 016-2011-SA | 2011-07-27 | Title IV on medical devices; Art. 124 (Class I documentation), Art. 125 (Class II documentation), Art. 136 (assessment caps in calendar days) |
| Modificatoria del D.S. N° 016-2011-SA | D.S. N° 016-2017-SA | 2017-06-07 | Substantially amends Arts. 12, 18, 26, 31, 40, 60, 62, 70, 81, 93, 94, 95, 104, 115, 124, 125, 127, 130 and others; replaces condiciones esenciales with principios esenciales throughout Title IV |
| Nuevo Texto Único de Procedimientos Administrativos (TUPA) del MINSA | D.S. N° 011-2026-SA | 2026-07-21 | New procedural text; review clocks set at 22 / 44 / 66 working days by risk level (specific article numbers pending verification; official publications prevail) |
| Ley de los Productos Farmacéuticos, Dispositivos Médicos y Productos Sanitarios | Ley N° 29459 | 2009-11-26 | Capítulo IV (sanitary registration) |
Regulatory information verified as of October 29, 2026.
3. Expert insights
Insight 1: the classification rules are a risk algorithm, not a product list.
D.S. N° 003-2020-SA replaced experience-based judgment with 18 classification rules, grouped into non-invasive devices, invasive devices, active devices and additional rules, with a technical lineage shared with the IMDRF framework and the EU MDR. The mechanical consequence is that different models within the same registration family can legitimately fall into different levels: catheters of the same brand may be separated because contact duration or route of invasion differs. If a company decides at project initiation by product family rather than by a model-to-rule mapping, the mismatch will only surface after submission, and what must then be remedied is not a set of documents but the entire procedural route. This is precisely why the first deliverable we prepare for every engagement is a classification matrix: once the level is set wrongly, every subsequent document is organized on a false premise, and the cost of correction grows with each stage of the program.
Insight 2: the level determines procedural depth, never exemption.
Inscription for Class I does not mean freedom from oversight. On the fee schedule of the TUPA, a Class I registration carries an official fee of S/ 1,438.70 and a re-registration of S/ 1,405.40, while Class II registration is S/ 1,593.20 and re-registration S/ 1,562.90. Both classes pay fees, both pass through a review clock, and both carry the continuing obligations of a registration holder. The difference lies in documentation depth: Art. 124 of D.S. N° 016-2011-SA sets the Class I dossier, Art. 125 the Class II dossier, and D.S. N° 016-2017-SA, published on 2017-06-07, amended both articles. Treating Class I as a zero-documentation track is a common starting point for rejection, because reviewers will still expect identification, labeling, safety and performance evidence proportionate to the device.
Insight 3: two clocks run in parallel, in different units, and must never be mixed.
Art. 136 provides assessment caps in calendar days: 30 for Class I, 60 for Class II and 90 for Class III/IV. The procedure table of D.S. N° 011-2026-SA, published on 2026-07-21, provides 22 / 44 / 66 working days. The former are statutory ceilings at the level of the regulation; the latter are operational clocks at the level of the procedure table. Working-day clocks also exclude the time consumed by Observaciones, the deficiency letters: the response window under the TUPA is 30 working days, and failure to respond within that period constitutes grounds for denial (specific article numbers pending verification; official publications prevail). Schedule with working days, argue with calendar days, and keep the two sets of numbers in their respective lanes. Total project duration has no statutory basis, and we estimate on a practical estimate basis: Class I/II typically run 3–6 months from acceptance to certificate, Class III/IV longer, extended accordingly where deficiency responses occur.
4. Practical recommendations
- Produce a classification memo before project launch: cite the specific rule number from Anexo 1 of D.S. N° 003-2020-SA for each model and state the reasoning, rather than writing only the word Class II.
- Plan resources backward from the level: prepare against the 22 working days clock for Class I, 44 working days for Class II and 66 working days for Class III/IV, and write the deficiency-response contingency for each tier in advance.
- Build a classification matrix for family submissions: split models that cross levels into separate submissions, so that higher-level models are not dragged down by lower-level dossiers or slower by higher-level demands.
- Align dossier depth with the amended articles: Art. 124 and Art. 125 were modified by D.S. N° 016-2017-SA, and reusing pre-2017 template archives will collide directly with the wording shift from condiciones esenciales to principios esenciales.
- Confirm official fees against the current TUPA schedule: the fee rows span S/ 1,438.70 – S/ 2,176.40 on 2026 figures; verify the corresponding procedure row before payment.
- Keep a single evidence trail: archive the classification memo, the matrix and the fee verification together so that any later audit of the pathway decision can be reconstructed without ambiguity.
5. Verification checklist
□ A classification determination has been issued for each model under the 18 classification rules of Anexo 1 of D.S. N° 003-2020-SA
□ It has been confirmed that Class I proceeds through inscription and Class II–IV through full registration, with no assumption of exemption from registration
□ The calendar-day caps of Art. 136 (30 / 60 / 90) have been distinguished from the TUPA working-day clocks (22 / 44 / 66)
□ The deficiency-response window of 30 working days has been built into the project schedule
□ Class I and Class II dossiers have been organized under Art. 124 / Art. 125 as amended by D.S. N° 016-2017-SA
□ The current TUPA fee row and official fee amounts have been verified
Regulatory information verified as of October 29, 2026.
GRZAN Regulatory Team
GRZAN provides registration support in Peru for manufacturers, importers and authorized representatives, covering pathway selection, classification, dossier preparation and regulatory maintenance. Contact: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us